ASTRAZENECA AND TARGACEPT ANNOUNCE TOP-LINE RESULTS FROM PHASE IIb STUDY OF AZD3480 IN COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA


ASTRAZENECA AND TARGACEPT ANNOUNCE TOP-LINE RESULTS FROM PHASE IIb STUDY OF
AZD3480 IN COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA

AstraZeneca and Targacept, Inc. today announced top-line results from a Phase
IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive
dysfunction in schizophrenia (CDS), known as the HALO trial.

AZD3480 did not meet the trial's criteria for statistical significance on the
primary outcome  endpoints, improvement on various cognitive domains measured by
the IntegNeuro computerized test battery. AZD3480 was generally well tolerated
in the study.  AstraZeneca and Targacept do not expect to progress AZD3480 into
Phase III studies for CDS.  

In addition to the HALO trial, AstraZeneca and Targacept previously announced
top-line results from a Phase IIb study of AZD3480 in mild to moderate
Alzheimer's disease, known as the Sirocco trial and are currently evaluating
AZD3480 in a Phase II exploratory study in attention deficit/hyperactivity
disorder (ADHD) in adults.  A decision by AstraZeneca with respect to potential
further development of AZD3480 in Alzheimer's disease or ADHD is now expected in
the first half of 2009, pending completion of the adult ADHD study and other
ongoing evaluations. 

“While this trial outcome did not meet our objectives, we continue to pursue
medicines that target neuronal nicotinic receptors (NNRs) with Targacept to
treat cognitive disorders,” said Bob Holland, Vice President and Head of the
Neuroscience Therapy Area, AstraZeneca.

AstraZeneca and Targacept also announced that the lead compound arising out of
the parties' preclinical research collaboration is poised to enter the clinic.
AstraZeneca plans by the end of 2008 to initiate a Phase I trial of AZD1446
(TC-6683), a product candidate selective for the alpha4beta2 NNR.  Under the
terms of the parties' collaboration agreement, AstraZeneca has agreed to make a
$2.0 million milestone payment to Targacept.

“We are obviously disappointed that AZD3480 did not meet our goals in the HALO
trial,” commented J. Donald deBethizy, Ph.D., President and Chief Executive
Officer of Targacept. “We thank AstraZeneca for its commitment to AZD3480 and
its investment in this pioneering work in an emerging area considered to be
critical in the treatment of patients with schizophrenia.  We look forward to
continuing our cognition-focused collaboration with AstraZeneca.”

- ENDS -

8 December 2008

Study Design 
The Phase IIb HALO trial was conducted by AstraZeneca under the terms of an
exclusive global license and research collaboration agreement. The trial was a
multi-center, randomized, double blind, placebo controlled, dose-finding study
conducted at approximately 70 enrolling sites in the United States and Canada. 
Subjects (n = 445) between 18 and 55 years of age who were active smokers and
taking medication from the class of drugs known as atypical anti-psychotics were
randomly assigned to one of three dose groups of AZD3480 or to placebo and dosed
over a 12-week period.  The primary outcome measures of the trial were change
from baseline after 12 weeks on various domains of cognition as measured by the
IntegNeuro computerized test battery.

About Cognitive Dysfunction in Schizophrenia 
Schizophrenia is a chronic, severe and disabling form of psychosis that, in
addition to symptoms such as delusions and hallucinations, is often marked by
impairments in cognitive functions such as attention, vigilance, memory and
reasoning.  These cognitive impairments play a primary role in the inability of
schizophrenic patients to function normally. It has been estimated that there
are 7.9 million schizophrenic patients in the world's seven major pharmaceutical
markets and that the majority of all schizophrenic patients are cognitively
impaired.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in research,
development, manufacturing and marketing of prescription pharmaceuticals and
supplier for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US $29.55 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infection product sales. AstraZeneca is listed in the Dow Jones
Sustainability Index (Global) as well as the FTSE4Good Index.  For more
Information visit www.astrazeneca.com

About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and
develops NNR Therapeutics (TM), a new class of drugs for the treatment of
central nervous system diseases and disorders. Targacept's product candidates
selectively modulate neuronal nicotinic receptors that serve as key regulators
of the nervous system to promote therapeutic effects and limit adverse side
effects. Targacept has product candidates in development for Alzheimer's
disease, cognitive dysfunction in schizophrenia, pain and depression, as well as
multiple preclinical programs. Targacept also has a cognition-focused
collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.
Targacept's news releases are available on its website at www.targacept.com


Contacts

AstraZeneca:

Media Enquiries US:
Jamie Smith		+1 302 885 5725

Media Enquiries UK:
Neil McCrae		+44 207 304 5045  (24 hours)
Chris Sampson	+44 20 7304 5130  (24 hours)
Sarah Lindgreen	+44 20 7304 5033  (24 hours) 	

Investor Enquiries UK:
Jonathan Hunt		+44 207 304 5087	mob: +44 7775 704032
Mina Blair		+44 20 7304 5084   	mob: +44 7718 581021
Karl Hard		+44 207 304 5322      	mob: +44 7789 654364

Investor Enquiries US:
Ed Seage			+1 302 886 4065   	mob: +1 302 373 1361
Jorgen Winroth		+1 212 579 0506   	mob: +1 917 612 4043
Peter Vozzo (MedImmune)  	+1 301 398 4358   	mob: +1 301 252 7518

Targacept:

Alan Musso, VP and CFO, Targacept, Inc. 
Tel: (336) 480-2186
Email: alan.musso@targacept.com

Michelle Linn, Linnden Communications
Tel: (508) 362-3087
Email: linnmich@comcast.net


# # #
GlobeNewswire